Silverarc Capital Management LLC Has $5.58 Million Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

Silverarc Capital Management LLC lifted its holdings in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 9.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,171,847 shares of the company's stock after purchasing an additional 526,495 shares during the period. Gossamer Bio accounts for about 1.2% of Silverarc Capital Management LLC's investment portfolio, making the stock its 27th biggest holding. Silverarc Capital Management LLC owned approximately 2.72% of Gossamer Bio worth $5,583,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Smith Moore & CO. lifted its stake in shares of Gossamer Bio by 32.7% in the fourth quarter. Smith Moore & CO. now owns 300,000 shares of the company's stock worth $271,000 after buying an additional 74,000 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Gossamer Bio by 1.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock valued at $1,123,000 after acquiring an additional 13,902 shares during the period. Geode Capital Management LLC grew its position in shares of Gossamer Bio by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock valued at $2,037,000 after purchasing an additional 38,084 shares during the last quarter. Finally, Monaco Asset Management SAM increased its stake in shares of Gossamer Bio by 39.5% in the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock worth $4,859,000 after purchasing an additional 1,520,721 shares during the period. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Stock Performance

GOSS traded down $0.02 on Friday, hitting $0.96. 2,464,392 shares of the stock traded hands, compared to its average volume of 1,575,783. The business has a fifty day moving average price of $1.10 and a two-hundred day moving average price of $0.98. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio, Inc. has a 52 week low of $0.50 and a 52 week high of $1.55. The firm has a market capitalization of $217.75 million, a PE ratio of -2.99 and a beta of 1.88.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.15). The business had revenue of $9.38 million during the quarter, compared to analyst estimates of $7.02 million. On average, research analysts predict that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GOSS has been the subject of several recent analyst reports. The Goldman Sachs Group decreased their target price on Gossamer Bio from $8.00 to $7.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a research note on Tuesday, March 18th. Finally, Wedbush reiterated an "outperform" rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Friday, March 14th.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.